Literature DB >> 26574500

Healthcare professionals are less confident in managing acute toxicity related to the use of new psychoactive substances (NPS) compared with classical recreational drugs.

D M Wood1, B Ceronie2, P I Dargan3.   

Abstract

BACKGROUND: The features of acute classical recreational drugs or new psychoactive substances (NPS) toxicity fall into three broad groups: (i) stimulant; (ii) hallucinogenic and (iii) depressant. Currently, there is no information available on healthcare professionals knowledge/confidence in managing the acute toxicity related to NPS use. AIM: We have compared knowledge and confidence of managing acute toxicity related to use of NPS with that seen with the use of to classical recreational drugs. DESIGN AND METHODS: Physicians/nurses completed a questionnaire survey to self-assess on a 5-point scale their knowledge (1-little knowledge; 5-very knowledgeable) and confidence (1-little confidence; 5-very confident) of managing acute toxicity related to the use of classical recreational drugs or NPS. Differences between knowledge and confidence for classical recreational drugs and NPS were assessed using paired Student's t-test; comparison between doctors, nurses and the frequency of managing acute classical recreational drug/NPS toxicity was assessed using unpaired Student's t-test.
RESULTS: One hundred and eighty-eight (82 physicians, 106 nurses) completed the survey. Classical drug compared with NPS knowledge: nurses 2.9 ± 1.0 vs. 2.1 ± 1.0, P  < 0.001; physicians 3.1 ± 0.8 vs. 2.1 ± 1.0, P < 0.001. There was no difference between nurses and physicians in classical drug (P = 0.11) or NPS (P = 0.89) knowledge. Confidence in managing classical drug toxicity compared with NPS confidence: nurses 3.0 ± 1.1 vs. 2.3 ± 1.1, P < 0.001; physicians 3.0 ± 0.9 vs. 2.1 ± 1.0, P < 0.001. There was no difference between nurses and physicians in classical drugs (P = 0.85) or NPS (P = 0.33) confidence.
CONCLUSIONS: Physicians/nurses are less confident in managing acute NPS toxicity. Management of toxicity is not dependent on knowing the drug/NPS, but should be on the basis of these clinical signs/symptoms. Training/education should focus on the concept of managing the pattern of toxicity that an individual presents with rather than the actual drug(s).
© The Author 2015. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26574500      PMCID: PMC4986425          DOI: 10.1093/qjmed/hcv208

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  8 in total

Review 1.  Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations.

Authors:  Fridtjof Heyerdahl; Knut Erik Hovda; Isabelle Giraudon; Christopher Yates; Alison M Dines; Roumen Sedefov; David M Wood; Paul I Dargan
Journal:  Clin Toxicol (Phila)       Date:  2014-10-31       Impact factor: 4.467

Review 2.  The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone).

Authors:  Paul I Dargan; Roumen Sedefov; Ana Gallegos; David M Wood
Journal:  Drug Test Anal       Date:  2011-07-13       Impact factor: 3.345

Review 3.  Understanding how data triangulation identifies acute toxicity of novel psychoactive drugs.

Authors:  D M Wood; P I Dargan
Journal:  J Med Toxicol       Date:  2012-09

4.  Prevalence of use and acute toxicity associated with the use of NBOMe drugs.

Authors:  David M Wood; Roumen Sedefov; Andrew Cunningham; Paul I Dargan
Journal:  Clin Toxicol (Phila)       Date:  2015-02       Impact factor: 4.467

5.  The European Drug Emergencies Network (Euro-DEN).

Authors:  D M Wood; F Heyerdahl; C B Yates; A M Dines; I Giraudon; K E Hovda; P I Dargan
Journal:  Clin Toxicol (Phila)       Date:  2014-03-21       Impact factor: 4.467

Review 6.  Novel psychoactive substances: how to understand the acute toxicity associated with the use of these substances.

Authors:  David M Wood; Paul I Dargan
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

Review 7.  Use and acute toxicity associated with the novel psychoactive substances diphenylprolinol (D2PM) and desoxypipradrol (2-DPMP).

Authors:  David M Wood; Paul I Dargan
Journal:  Clin Toxicol (Phila)       Date:  2012-08-10       Impact factor: 4.467

Review 8.  Mephedrone (4-methylmethcathinone): what is new in our understanding of its use and toxicity.

Authors:  David M Wood; Paul I Dargan
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-04-28       Impact factor: 5.067

  8 in total
  7 in total

1.  The challenge of the novel psychoactive substances: How have we responded and what are the implications of this response?

Authors:  David M Wood; Paul I Dargan
Journal:  Br J Clin Pharmacol       Date:  2020-03-06       Impact factor: 4.335

2.  Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances.

Authors:  Elena Deligianni; Omari J Daniel; John M Corkery; Fabrizio Schifano; Lisa A Lione
Journal:  Br J Clin Pharmacol       Date:  2020-01-09       Impact factor: 4.335

3.  "Hot" and "Cold" Cognition in Users of Club Drugs/Novel Psychoactive Substances.

Authors:  George Savulich; Owen Bowden-Jones; Robert Stephenson; Annette B Brühl; Karen D Ersche; Trevor W Robbins; Barbara J Sahakian
Journal:  Front Psychiatry       Date:  2021-03-24       Impact factor: 4.157

Review 4.  New psychoactive substances: a review and updates.

Authors:  Abu Shafi; Alex J Berry; Harry Sumnall; David M Wood; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2020-12-17

5.  Exploration of the Use of New Psychoactive Substances by Individuals in Treatment for Substance Misuse in the UK.

Authors:  Rosalind Gittins; Amira Guirguis; Fabrizio Schifano; Ian Maidment
Journal:  Brain Sci       Date:  2018-03-30

6.  High-Throughput Qualitative and Quantitative Drug Checking by MALDI HRMS.

Authors:  Timothée Joye; Christèle Widmer; Roxane Morger Mégevand; Serge Longère; Marc Augsburger; Aurélien Thomas
Journal:  Front Chem       Date:  2020-08-25       Impact factor: 5.221

Review 7.  Neuronal and peripheral damages induced by synthetic psychoactive substances: an update of recent findings from human and animal studies.

Authors:  Giulia Costa; Maria Antonietta De Luca; Gessica Piras; Jacopo Marongiu; Liana Fattore; Nicola Simola
Journal:  Neural Regen Res       Date:  2020-05       Impact factor: 5.135

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.